Abstract library

1031 results for "clinical outcome".
#136 Prevalence, severity and clinical outcome of malnutrition in gastroenteropancreatic neuroendocrine tumors
Introduction: Malnutrition is well-known to unfavorably influence clinical prognosis in patients (pts) with malignant diseases. However, in patients with neuroendocrine tumors (NET) prevalence and outcome of malnutrition are unknown although the gastroenteropancreatic system is most frequently involved.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr Sebastian Maasberg
#513 Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus
Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Francesca Spada
Authors: Spada F, Pisa E, Lorizzo K, Barberis M, ...
Keywords: mTOR
#1773 Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract
Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Lee K, Kim K P, Chang H M, ...
#1200 Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Data from the German NET-Register
Introduction: Everolimus (EVE) has importantly impacted the treatment (Tx) of mostly pancreatic NEN.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Authors: Pape U F, Bacher M, Fottner C, Lahner H, ...
Keywords: everolimus, outcome
#128 Multidisciplinary reference centers: the need for combined expertise in the diagnosis and treatment of neuroendocrine tumors
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies with increasing incidence (Yao et al. J Clin Oncol 2008;26:3063–72). Multidisciplinary reference centers (MRCs) can potentially offer better clinical outcomes by integrating and coordinating expert care from many specialties, reducing delays in treatments and referrals, and allowing for accrual to clinical trials. MRCs have achieved improved outcomes in ovarian, breast and lung cancers (Pollock. Ann Surg 2008;248:510–6; Gabel et al. Cancer 1997;79:2380–4; Forrest et al. Br J Cancer 2005;93:977–8). Despite this, MRCs focusing on NETs are uncommon.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#363 Clinicopathological characteristics are capable of predicting long-term outcome of gastrointestinal neuroendocrine tumours in Germany
Introduction: Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasm. Throughout the last decades the classification of NET has been both difficult and incoherent. Therefore making prognostic straticifation often difficult.
Conference:
Category: Basic
Presenting Author: Sebastian Maasberg
Keywords: outcome
#1803 Type 3 Gastric Neuroendocrine Neoplasms: Relationship Between Tumor Size, Ki67 and Clinical Outcome
Introduction: Sporadic type 3 gNENs are usually malignant with high metastatic potential, mostly large, with a high grade histology. However, little is known on the relationship between tumor size, proliferative index Ki67, and clinical outcome
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Francesco Panzuto
#1823 Effects of Low-Doses Aspirin on Clinical Outcome and Disease Progression in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results of a Multicentric Retrospective Study
Introduction: The chemopreventive effect of aspirin (ASA) have been observed in the setting of colorectal cancer. The impact of aspirin use on clinical outcome of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP NEN) has not been evaluated yet
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: dr Sara Massironi
Keywords: NEN, ASA
#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#592 Expression of PTEN and mTOR in Pancreatic Neuroendocrine Tumors and Their Clinical Significance
Introduction: mTOR is currently under investigation as a potential target for anticancer therapy. Loss of PTEN, the negative regulators of the PI3K-Akt-mTOR pathway, have been associated with cancer.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Ji Y, Zhao J, Xu X, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.